Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluriaBernd Höppe, Craig B. Langman, Gesa Schalk et al.|Kidney International|2021Cited by 90
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A. Hulton, John C. Lieske, Jaap W. Groothoff et al.|Kidney International Reports|2021Cited by 32
12-Month Analysis of ILLUMINATE-A, a Phase 3 Study of Lumasiran: Sustained Oxalate Lowering and Kidney Stone Event Rates in Primary Hyperoxaluria Type 1Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff et al.|Journal of the American Society of Nephrology|2020Cited by 4
Analyse à 12 mois d’ILLUMINATE-A, une étude de phase 3 du lumasiran : réduction durable de l’oxalate et des taux d’évènements de calculs rénaux dans l’hyperoxalurie primitive de type 1Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff et al.|Néphrologie & Thérapeutique|2021Cited by 0